Cancer Clinical Trials

Clinical Research

Clinical trials are the final step in a long process that often begins in the lab. Many cancer treatments used today are results of past clinical trials. Cancer clinical trials are key to developing new methods to prevent, detect, and treat cancer. It is through clinical studies that researchers can determine whether new treatments are safe, effective, and if they work better than current treatments. When you take part in a clinical trial, you add to our knowledge about cancer and help improve cancer care. Learn more about clinical trials through the National Cancer Institute.

The Bassett Cancer Institute has been providing access to cutting edge treatments in a convenient, local setting for over 40 years. Bassett Healthcare Network's membership in the Eastern Cooperative Oncology Group (ECOG) allows access to numerous clinical trials through the Clinical Trials Support Unit (CTSU), funded by The National Institutes of Health (NIH) and The National Cancer Institutes (NCI).

Why Should I Consider a Clinical Trial?

Clinical trials allow your cancer treatment team to use clinical research in order to treat your form of cancer. Participants of clinical studies receive high-quality care that experts believe may become a new standard of cancer treatment, and are closely monitored. Our oncologists may recommend a clinical trial as an alternative to current standards of care, such as chemotherapy, immunotherapy, radiation therapy, or surgical removal of the cancer cells. We do this because we believe that there are potentially better options than these proven treatments. If you would prefer to decline participating in a clinical trial, you will still receive the gold standard of care.

ACT (About Clinical Trials) is a great resource for patients considering participating in a clinical trial. The experts and participants in these videos help educate patients about clinical trials, including what questions to ask about available treatment options, what to consider before participating in a trial, and how to know if a trial may be the right treatment for them. 

If you are interested in joining a specific clinical trial, or would like to research results of past clinical trials, visit clinicaltrials.gov to learn more.

Cancer Clinical Trials at Bassett Healthcare Network

Available Clinical Studies

Learn more about our current clinical studies:

Connect® MDS/AML Disease Registry
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT01688011
(Project 1246938)
Eric Bravin, M.D.

A011401
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

For more information regarding this trial, visit the ClinicalTrials.gov Identifier.
NCT02750826
(Project 1246873) 
Eric Bravin, M.D.


A011502
A Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02927249
(Project 1246871) 
Eric Bravin, M.D.


A221505
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03414970
(Project 1494080) 
Julia Manzerova, M.D.


CCTG MA.39
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03488693
(Project 1525614)
Julia Manzerova, M.D.


NRG-BR003

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node Negative Triple-Negative Invasive Breast Cancer

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02488967
(Project 1246890) 
Venu Thirukonda, M.D.


NSABP B-51
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT01872975
(Project 1246932)
Timothy Korytko, M.D.


S1703

A Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Markers Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03723928
(Project 1350363) 
Eric Bravin, M.D.

A021502
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02912559
(Project 1246881)
Eric Bravin, M.D.  


A021703
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04094688
(Project 1520150)
Eric Bravin, M.D.

A031704 
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03793166
(Project 1442850)
Eric Bravin, M.D.

LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03851445
(Project 1368750)
Eric Bravin, M.D.


S1400F
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03373760
(Project 1246956)
Eric Bravin, M.D.


S1800A
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Non-Matched Sub-Study)

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03971474
(Project 1447130)
Eric Bravin, M.D.


S1900A
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03845296 
(Project 1389376)
Eric Bravin, M.D.


A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02194738
(Project 1246946)
Eric Bravin, M.D.


A081105
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02193282
(Project 1246947)
Eric Bravin, M.D.


E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02201992
(Project 1246948)
Eric Bravin, M.D.

EA6134
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02224781
(Project 1246965)
Eric Bravin, M.D.


EA6141 
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (Temporarily closed to accrual)

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02339571
(Project 1246966)
Eric Bravin, M.D.


S1801
RA Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03698019
(Project 1246966)
Eric Bravin, M.D.

NRG-GU005
Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03367702
(Project 1363197) 
Timothy Korytko, M.D.


NRG-GU006
A Phase II Double Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamode in Recurrent Prostate Cancer

For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03371719
(Project 1297423) 
Timothy Korytko, M.D.

Call or Email to Learn More About Participating in a Clinical Trial

Call our specialists at 1-877-547-1750, or email us at cancerclinicaltrials@bassett.org to learn more about participating in a cancer clinical trial. 

Bassett Healthcare Network’s oncologists offer cancer clinical throughout Central New York, including in Little Falls, Cobleskill, Delhi, Cooperstown, Oneonta, and Herkimer.

Locations

Bassett Medical Center

1 Atwell Road
Cooperstown, NY 13326-1394

(607) 547-3456
Bassett Medical Center